top of page
Evicure_logo_logo_color (002).png
ev-removebg-preview_edited.png

Therapeutic capabilities

Carrying endogenous therapeutic cargo

targeting-removebg-preview.png

Targeting ability

Homing ability to tumor sites

multi_faceted_icon-removebg-preview.png

Robust and multi faceted

Can be combined with exogenous therapies

cargo_icon-removebg-preview.png

Protecting cargo

Minimal degradation in body fluids and circulation

non_immunogenic_-_off_the_shelf-removebg-preview.png

Non-Immunogenic

Low expression of MHC class I and class II – "off the shelf" products

stability_2-removebg-preview.png

Enhanced stability

Stable in body fluids, easy to store, handle, and administer

PK_PD-removebg-preview-removebg-preview.png

Prolonged PK/PD profile

superior to other delivery systems (liposomes, nanoparticles)

drug_safety-removebg-preview.png

Safety

Cellular sources demonstrated safety in multiple pre-clinical studies and clinical trials

AI-based_scale_up-removebg-preview.png

High batch reproducibility

AI-based real-time controlled EV production process

Screenshot 2024-08-04 at 11_edited.jpg

 EviCure's Advantages
For Targeted Cancer Therapy

EviCure_back_Color-02.png

EviCure’s EV Advantages

 For targeted cancer therapy

Want to know more?

bottom of page